Interestingly, these beneficial effects of semaglutide once a week were also confirmed in two trials, in which patients were switched from other GLP1-RAs to weekly subcutaneous semaglutide (Okamoto et al., 2021; Nomoto et al., 2023), indicating that semaglutide may be the GLP1-RAs of choice in patients with NAFLD. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.